The PATH (Predictive Approaches to Treatment effect Heterogeneity) Statement was developed to promote the conduct of, and provide guidance for, predictive analyses of heterogeneity of treatment effects (HTE) in clinical trials. The goal of predictive HTE analysis is to provide patient-centered estimates of outcome risk with versus without the intervention, taking into account all relevant patient attributes simultaneously, to support more personalized clinical decision making than can be made on the basis of only an overall average treatment effect. The authors distinguished 2 categories of predictive HTE approaches (a "riskmodeling" and an "effect-modeling" approach) and developed 4 sets of guidance statements: criteria to determine when riskmodeling approaches are likely to identify clinically meaningful HTE, methodological aspects of risk-modeling methods, considerations for translation to clinical practice, and considerations and caveats in the use of effect-modeling approaches. They discuss limitations of these methods and enumerate research priorities for advancing methods designed to generate more personalized evidence. This explanation and elaboration document describes the intent and rationale of each recommendation and discusses related analytic considerations, caveats, and reservations.
I n medical care, treatment decisions made by clinicians and patients are generally based-implicitly or explicitly-on predictions of comparative outcome risks under alternative treatment conditions. Randomized controlled trials (RCTs), widely accepted as the gold standard for determining causal effects, have provided the primary evidence for these predictions. However, there is mounting recognition within evidence-based medicine of the limitations of RCTs as tools to guide clinical decision making at the individual patient level (1) (2) (3) (4) . Although historically the overall summary result from randomized trials ("average treatment effect") has been the cornerstone of evidence-based clinical decisions, interest is growing in understanding how a treatment's effect can vary across patients-a concept described as heterogeneity of treatment effects (HTE) (5) (6) (7) (8) (9) (10) (11) .
Much literature exists on the limitations of conventional "1-variable-at-a-time" subgroup analyses, which serially divide the trial population into groups (for example, male vs. female or old vs. young) and examine the contrast in the treatment effect across these groups (12) (13) (14) (15) (16) (17) (18) (19) (20) (21) (22) . The limitations include risks for false-negative and false-positive results due to low power for statistical interactions, weak prior theory on potential effect modifiers, and multiplicity (4, 10, (23) (24) (25) . These analyses are also incongruent with the way clinical decision making occurs at the level of the individual patient, because patients have multiple attributes simultaneously that can affect the tradeoffs between the benefits and harms of the intervention. Individual patients thus belong to multiple subgroups, each of which may yield a different estimate of the treatment effect (4, 10) .
The PATH (Predictive Approaches to Treatment effect Heterogeneity) Statement offers guidance relevant for "predictive" approaches to HTE analysis (26) that are designed to address some of the limitations mentioned in the previous paragraph. The goal of predictive HTE analysis is to provide individualized predictions of treatment effect, specifically defined by the difference between expected potential outcomes of interest with one intervention versus an alternative (4, 8) . We refer to this as the "individualized treatment effect." We avoid the term "individual treatment effects" because this latter term confusingly suggests that treatment effects can be estimated at the person level; such effects are inherently unobservable in parallel-group clinical trials because only 1 of 2 counterfactual potential outcomes can be observed (10, 27) . Individualized treatment effects have also been termed "conditional average treatment effects" (28) , denoting that they are the averaged treatment effect in a subpopulation (that is, conditioned on a set of covariates). However, for prediction, we are specifically interested in identifying the best conditional average treatment effect given all available patient characteristics, where "best" is defined as that which best discriminates between future patients who do and do not benefit from a treatment to optimize decision making for individual patients (29). By accounting for multiple variables simultaneously, predictive HTE analysis is foundational to the concept of personalization in evidence-based medicine (4) . Statement guidance focuses on identifying "clinically important HTE" (4, 7, 10) , or variation in the risk difference across patient subgroups that may be sufficient to span important decision thresholds that reflect treatment-related harms and burdens. The statement offers guidance on 2 distinct approaches to predictive HTE analysis (4) . With a "risk-modeling" approach, a multivariable model that predicts risk for an outcome (usually the primary study outcome) is first identified from external sources (an "external model") or developed directly on the trial population without a term for treatment assignment (an "internal model"). This prediction model is then applied to disaggregate patients within trials to examine risk-based variation in treatment effects. In a second approach, "effect modeling," a model is developed on RCT data with inclusion of a treatment assignment variable and potential inclusion of treatment interaction terms. These more flexible effect-modeling approaches have the potential to improve discrimination of patients who do and do not benefit, but they are especially vulnerable to overfitting and false discovery of promising subgroup effects (or they require very large databases that are well powered for the detection of interaction effects) (30). Both approaches can be used to predict individualized treatment effects-that is, the difference in expected outcome risks under 2 alternative treatments, conditional on important clinical variables. A fuller introduction to risk and effect modeling is presented in prior literature (4) .
In this PATH Statement explanation and elaboration, we expand on the intent and motivation (and reservations) regarding the statements, criteria, considerations, and caveats. Recommendations are explained in more detail and accompanied by clinical applications of selected methods and supporting methodological evidence where relevant. The Glossary defines terms relevant to these methods.
CLARIFICATION OF TERMS AND PATH STATEMENT SCOPE
The term "heterogeneous treatment effects" has been used in the literature in different ways. In this article, we define HTE as nonrandom variation in treatment effects across levels of a covariate (that is, a patient attribute or a score comprising multiple attributes), as measured on a selected scale, against a clinical outcome. It corresponds to the epidemiologic concept of effect measure modification but applies specifically to treatment effects. In clinical trials, HTE is identified by contrasting treatment effects on a chosen scale between subgroups and testing for statistical interactions. Of note, HTE, effect measure modification, and statistical interaction are all "scaledependent" concepts-that is, their presence or absence depends on what scale is selected to measure treatment effect (31) . The scale dependence of HTE is illustrated in Figure 1 , which contrasts 3 analyses (the first showing HTE only on the absolute scale, the second only on the relative scale, and the third on both). To underscore the scale dependence of HTE, we also show the results of a risk-Glossary Effect modification: Occurs when the magnitude of the effect of the primary treatment or exposure on an outcome differs depending on the level of a third variable (e.g., patient characteristics). In the presence of effect modification, the use of an overall effect estimate is inappropriate. Heterogeneity of treatment effects (HTE): Nonrandom variation in the direction or magnitude of a treatment effect, measured using clinical outcomes. HTE is fundamentally a scale-dependent concept, and therefore, for clarity, the scale should generally be specified. Clinically important HTE: Occurs when variation in the risk difference across patient subgroups spans an important decision threshold, which depends on treatment burden (including treatment-related harms and costs). It is generally assessed on the absolute scale. Statistically significant HTE: Occurs when the effect of an intervention is found to differ across levels of a covariate on a selected scale as evaluated against a null hypothesis statistical test. In regression analysis, HTE is typically tested on a relative scale (e.g., odds ratio or hazard ratio) by examining the statistical significance of an interaction term between a covariate and treatment. Causal interaction: Occurs when manipulating a covariate would change the effect of the primary treatment on the outcome. Statistically significant covariate-by-treatment interaction does not necessarily imply causal interaction. Predictive HTE analysis: The main goal of predictive HTE analysis is to develop models that can be used to predict which of 2 or more treatments will be better for a particular individual. Risk-modeling approach: An approach to predictive HTE analysis where a multivariable model that predicts the risk for an outcome (usually the primary study outcome) is applied to disaggregate patients in trials to examine risk-based variation in treatment effects. External models vs. endogenous or internally derived models: An external risk model has been developed from an external trial or cohort population that can be applied for HTE analysis of the trial. An endogenous or "internal" risk model is one developed directly on the trial population that does not include a term for treatment assignment. Treatment effect-modeling approach: An approach to predictive HTE analysis that develops a model directly on randomized trial data to predict treatment effects (i.e., the contrast in outcome risks under 2 alternative treatment conditions). Unlike in risk modeling, the model incorporates a term for treatment assignment and permits the inclusion of treatment-by-covariate interaction terms. Net benefit: A decision analytic measure that puts benefits and harms on the same scale. This is achieved by specifying an exchange rate based on the relative value of benefits and harms associated with interventions. The exchange rate is related to the probability threshold to determine whether a patient is classified as positive or negative for a model outcome, or (when applied to trial analysis) as treatment-favorable vs. treatmentunfavorable. Overfitting: A key threat to the validity of a model where predictions do not generalize to new persons outside the sample under study.
Overfitting occurs when a model conforms too closely to the idiosyncrasies or "noise" of the limited data sample on which it is derived. Penalized regression: A set of regression methods, developed to prevent overfitting, in which the coefficients assigned to covariates are penalized for model complexity. Penalized regression is sometimes referred to as shrinkage or regularization. Examples of penalized regression include LASSO (least absolute shrinkage and selection operator) regression, ridge regression, and elastic net regularization. Reference class: A group of similar case patients that is used to make predictions for an individual case patient of interest. The "reference class problem" refers to the fact that similarity can be defined in an indefinite number of ways. Subgroup analysis: An analysis that examines whether specific patient characteristics modify the effects of treatment on an outcome. Testimation bias (also known as the "winner's curse"): Refers to the fact that the effect sizes of newly discovered true (non-null) associations are inherently inflated on average. Testimation bias arises because of the use of thresholds in the process of discovering associations. Inflation is usually expected when both 1) an association has to pass a certain threshold of statistical significance to be deemed positive and 2) the study that leads to the discovery has suboptimal power.
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modeling analysis of the DPP (Diabetes Prevention Program) trial, which tested lifestyle modification and metformin against usual care for prevention of diabetes ( Figure 2 ). Although only 1 tested therapy showed statistically significant HTE on the relative (hazard ratio) scale, both therapies had substantial HTE on the clinically important absolute scale. The Glossary defines key terms described here and elsewhere in the PATH Statement and explanation and elaboration document (26) .
HTE ANALYSIS FOR CAUSAL INTERACTION VERSUS FOR PREDICTION AND DECISION MAKING
We also note that HTE (and statistical interactions) are used to make 2 very different kinds of inferences: causal inferences (for example, regarding causal or biological interaction) and inferences for clinical decision making. Although the importance of statistical interac- tions is often stressed for HTE analysis, these inferences are only weakly related to the presence of "statistically significant HTE." Statistical interactions should not be confused with causal interactions, and statistically significant HTE should also not be conflated with clinically important HTE. These issues are described briefly in the following paragraphs.
In regression models examining HTE, causal inferences depend on interpretation of model inputs (that is, model covariates). The PATH guidance does not address causal interpretations of HTE. These analyses are important for identifying biomarkers that might biologically interact with therapy. Many methodologists believe that interaction on a multiplicative (relative) scale 
0.1
This figure presents HTE analysis of the DPP (Diabetes Prevention Program) trial as a function of baseline risk (32) . Event rates (top), hazard ratios (middle), and absolute effects (bottom) are shown. Both lifestyle modification (left) and metformin (right) are compared with usual care as a function of baseline risk. For lifestyle modification, a consistent 58% reduction in the hazard of developing diabetes over 3 y was found across all levels of risk. This consistent relative effect yields HTE on the absolute scale of potential clinical importance. In contrast, the effects of metformin are heterogeneous on both the hazard ratio scale and the absolute scale. Penalized splines were used to model the relationship between the linear predictor of risk and the time-to-event outcome. Vertical lines denote 95% CIs, and P values are based on the null hypothesis of no effect modification tested using the linear predictor of risk in a Cox model. In the hazard ratio graphs, the dashed lines show the average effects in the trial and the horizontal lines at 1.0 refer to the null effect on this scale. The horizontal lines at 0 in the absolute risk reduction graphs refer to the null effect on this scale. Prediction of incident diabetes with an external model derived from the Framingham cohort yielded a similar pattern (33) . HTE = heterogeneity of treatment effect; Q1 = first risk quarter (lowest); Q2 = second risk quarter; Q3 = third risk quarter; Q4 = fourth risk quarter (highest).
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is stronger evidence in support of a causal interaction than interaction on an absolute scale (although this is by no means a universal view) (34 -40) . Nevertheless, we note that treatment-by-covariate interactions (on any scale) are generally descriptive measures of association (when the covariate is not randomly assigned, as in a factorial trial) because an interacting covariate may be acting as a proxy for many measured and unmeasured variables. To attribute a change in the treatment effect to the covariate, we would need to control for all relevant differences in these other variables (that is, observed and unobserved confounders) across levels of the subgrouping factor. In any event, demonstrating causal interaction is not necessary for "predictive" HTE analyses that seek to target therapies to those who most benefit. In regression models examining HTE, inferences for clinical decision making depend on interpretation of model outputs. Because of this, such analyses have been called "predictive" HTE analyses (4, 8) . The PATH guidance is limited to predictive approaches to HTE. The goal of predictive HTE analysis is to develop models that can be used to predict which of 2 or more treatments will be better for a particular individual, taking into account multiple relevant variables (4, 8) . Clinically important HTE occurs when variation in the risk difference across patient subgroups spans a decisionally important threshold, which depends on treatment burden (including treatment-related harms and costs). It is generally assessed on the absolute scale, regardless of the scale of the analysis. Figure 1 illustrates the scale dependence of effect heterogeneity. We also note that controlling for confounding factors (that is, factors that differ between levels of the subgrouping variable) is not necessary for prediction (35, 41) .
A new term, "risk magnification," has recently been coined to describe a method of identifying high-risk, high-benefit patients (42, 43) . This approach depends on the observation that relative effects (and, in particular, those on the odds ratio scale) are often more stable than absolute effects (44 -46) . Risk magnification is distinct from the risk-modeling approach described here because it can be applied without any data based on the assumption of a constant relative treatment effect. Indeed, the use of the pooled cohort equations (47) (also known as the atherosclerotic cardiovascular disease risk estimator) to target statin therapy to patients at high risk for coronary heart disease might be described as an application of "risk magnification." Because many (observed and unobserved) patient attributes change across risk levels and because the causes of the outcomes may also change, the assumption of a consistent treatment effect across all levels of risk is a strong assumption that should ideally be examined using randomized data. In addition, the rate of adverse events may also differ across levels of baseline risk (recommendation 9 in Figure 3 of the PATH Statement [26] ). Examining randomized data stratified by a risk model also permits these other (nonprimary) outcomes to be examined across levels of risk.
PATH STATEMENT CRITERIA FOR WHEN RISK MODELING IS LIKELY TO BE OF VALUE
Included Criteria
The following criteria identify the features of the data, modeling, and clinical decisions that are common to scenarios in which the application of predictive HTE analyses to treatment comparisons is likely to be relevant for individualized clinical decision making ( Figure  2 of in the PATH Statement [26] ). The motivation and reservations regarding these criteria are elaborated.
When an overall treatment effect is well established. (Subgroup results [including risk-based subgroup results] from overall null trials should be interpreted cautiously.)
When clinical trials are null, researchers may be tempted to find subgroups of patients in whom the treatment might work. However, clinically important This figure depicts the anticipated influence of a risk-modeling approach in 2 trials testing different treatments in the same population, one (treatment A) with a slightly favorable benefit-harm tradeoff and the other (treatment B) with an extremely favorable benefit-harm tradeoff. Under both conditions, the control event rate is 25% and the MCSD (i.e., the absolute benefit that would justify the experimental therapy) is 3 percentage points. (For simplicity, we show a single MCSD, with gray shading corresponding to portions of the population that should not be treated, but this value varies according to individual patient values and preferences.) A risk-modeling approach would be of substantially greater value for the trial of treatment A, with the slightly favorable tradeoff (RRR, 0.15; absolute risk difference, 3.75% [just above the MCSD]), than for the trial of treatment B, with the extremely favorable tradeoff (RRR, 0.50; risk difference, 12.5% [substantially above the MCSD]). The distributions show the anticipated risk differences that emerge with a constant RRR when the same moderately predictive risk prediction model (i.e., with a c-statistic of about 0.70) is applied to the population. In the slightly favorable treatment condition (A), harms outweigh benefits in almost half of the trial population (43%) despite overall results showing benefit on average. In the extremely favorable treatment condition (B), treatment remains worthwhile in almost the entire population (97%). Thus, applying the risk-modeling approach is very valuable in the low-benefit condition because it reclassifies many patients as treatment-unfavorable who would otherwise have been treated on the basis of the overall result. MCSD = minimal clinically significant difference; RRR = relative risk reduction.
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Annals.org Annals of Internal Medicine subgroup effects discovered through risk modeling are likely to be rare when treatment efficacy has not been established. For example, among 18 null trials in a recent study, risk modeling did not yield clinically informative results on any (48) . More "aggressive" effect-modeling approaches (that is, those reliant on including treatment-bycovariate interaction terms within a prediction model) may identify groups of patients who seem to benefit, but such approaches are also likely to yield spurious false-positive results (28, 49) . Such "treatment-favorable" groups may be suggested by pure chance and are aggravated by multiple testing, even when treatments have no effect whatsoever (30). Thus, predictive HTE analyses are more appropriately done on interventions for which an overall effect has been established. Despite a tendency to focus on any subgroup with a positive effect in an otherwise null trial, in the absence of strong, a priori clinical justification, predictive HTE analyses on null trials are unlikely to lead to reliable clinical evidence. Possible exceptions to this general rule are interventions with known treatment-related harms that mediate primary outcomes in the treatment group and might nullify an overall effect. For example, angiotensin-converting enzyme inhibitors both cause and prevent renal insufficiency, thrombolytic therapy both causes (via hemorrhage) and prevents (via reperfusion) functional disability in patients presenting with acute stroke (50) , carotid surgery can both cause and prevent ischemic stroke in patients with carotid stenosis (51) , and antiarrhythmic agents both cause and prevent serious cardiac arrhythmias (52, 53) . In these circumstances, even when trials are null overall for the average treatment effect, risk models may be helpful in disaggregating patients who benefit from those who are harmed, through application of either an outcome risk model or a model identifying patients at high risk for treatment-related harm (that is, for "treatment deselection") (50, 54, 55) . Such an approach is possible particularly when the predictors of outcome risk are poorly (or negatively) correlated with predictors of risk for treatment-related harm. For example, excluding patients at high risk for thrombolytic-related intracranial hemorrhage in stroke (such as older patients with higher blood pressure) may uncover benefit in patients at lower risk (50).
2. When the benefits and harms or burdens of a given intervention are finely balanced (that is, of similar magnitude on average), increasing the sensitivity of the treatment decision to risk prediction.
Risk models are more likely to be useful when they support a particular "risk-sensitive" decision. This criterion corresponds to the observation that a prediction model or decision rule has maximum expected utility when the decision threshold is at or near the mean risk in the population (56, 57) . The threshold depends on clinical context and involves weighing the expected benefits against the expected harms or costs of a decision. This assessment can be done with formal decision analysis but is more often done informally.
The idea that the value of a risk model is higher for decisions where the threshold is near the population mean can be intuitively understood by considering that this value depends on the proportion of patients for whom the optimal treatment switches from the treatment that is better on average to the alternative given their model-estimated risk, and by considering the benefits that accrue to those switching (58 -60). Beyond measuring model accuracy, various methods have been proposed to evaluate the potential effect of model use on a particular decision, including risk stratification tables (61), relative utility curves (62), predictiveness curves (63), and decision curves (59) .
This discussion with respect to risk prediction also fully applies to benefit prediction. When the overall average benefit in a trial is balanced by the average treatment-related harms and costs (that is, when net benefit is near 0), any additional prognostic or predictive information is likely to be especially useful for determining the better therapy for a particular patient.
The relative utility of risk prediction when average risk is near versus far from a threshold is described schematically in Figure 3 , which shows the distribution of expected benefits when a risk model with a c-statistic of 0.70 is applied to a population with an average risk of 25%. We consider the following 2 treatment conditions: 1) a treatment with a moderate average treatment effect (relative risk reduction, 15%; risk difference, 3.8%) and an average benefit-harm tradeoff that is slightly favorable (vs. a minimal clinically important difference of 3%) and 2) a treatment with a large treatment effect (relative risk reduction, 50%; risk difference, 12.5%) and an average benefit-harm tradeoff that is clearly favorable. All else being equal, the net benefit of risk modeling would be much greater when benefit-harm tradeoffs are more finely balanced because risk stratification would reveal many patients (almost half of the trial population in the first schematic example) whose risk-specific optimal treatment differs from the treatment that is best on average. Preliminary evidence from careful simulations or even simple algebraic calculations (Figure 4 , left) using plausible assumptions may be important in motivating research and should generally be included in research proposals and protocols.
We acknowledge that the presentation of a single threshold is a simplification because the threshold is sensitive to patient values and preferences and because treatment harms and burdens are likely to vary across risk groups. For example, the CHADS 2 score (and its variants) is used to target anticoagulation to patients with nonvalvular atrial fibrillation, but patients with higher CHADS 2 scores are also known to be at higher risk for anticoagulation-related hemorrhage (65) . Given the potential (positive or negative) correlation between benefits and harms, we recommend that harms be reported in each risk stratum to support stratum-specific evaluation of benefit-harm tradeoffs (recommendation 9 in Figure 3 of the PATH Statement [26] ).
When treatments are associated with a nontrivial amount of serious harm or burden, increasing the importance of careful patient selection.
This criterion is related to the previous 2, in that HTE will be most important to decision making in the RESEARCH AND REPORTING METHODS . Regardless of whether this interaction is statistically significant, examination of treatment effects on the absolute risk difference scale (bottom) shows harm in the low-risk group and very substantial benefit in the high-risk group, both of which are obscured by the overall summary results. Conventional "1-variable-at-a-time" subgroup analyses are typically inadequate to disaggregate patients into groups that are sufficiently heterogeneous for risk, so benefit-harm tradeoffs can misleadingly seem to be consistent across the trial population. Although this figure shows idealized relationships between risk and treatment effects, these relationships will be sensitive to how risk is described (i.e., what variables are in the risk model). Baseline risk has a logitnormal distribution, with μ = Ϫ3 and = 1 (the log odds are normally distributed). Adapted from reference 3. Q1 = first risk quarter (lowest); Q2 = second risk quarter; Q3 = third risk quarter; Q4 = fourth risk quarter (highest). B. Stratified results of RITA-3 (Randomized Intervention Trial of unstable Angina 3) (64). The RITA-3 trial (n = 1810) tested early intervention vs. conservative management of non-ST-segment elevation acute coronary syndrome. Results for the outcome of death or nonfatal myocardial infarction at 5 y are shown, stratified into equal-sized risk quarters using an internally derived risk model; the highest-risk quarter is substratified into halves (groups 4a and 4b). Event rates with 95% CIs (top), odds ratios (middle), and risk differences (bottom) are shown. The risk model comprises the following easily obtainable clinical characteristics: age, sex, diabetes, prior myocardial infarction, smoking status, heart rate, STsegment depression, angina severity, left bundle branch block, and treatment strategy. As in the schematic diagram to the left, the average treatment effect seen in the summary results (horizontal dashed line in middle and bottom panels) closely reflects the effect in patients in risk group 3, whereas half of patients (risk groups 1 and 2) receive no treatment benefit from early intervention. Absolute benefit (bottom) in the primary outcome was very pronounced in the eighth of patients at highest risk (risk group 4b). A statistically significant risk-bytreatment interaction can be seen when results are expressed in the odds ratio scale (middle) (the interaction P value is from a likelihood ratio test for adding an interaction between the linear predictor of risk and treatment assignment). Such a pattern can emerge if early intervention is associated with some procedure-related risks that are evenly distributed over all risk groups, eroding benefit in low-risk but not high-risk patients, as illustrated schematically in the left panel.
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presence of a qualitative interaction-meaning that some patients benefit while others are harmed. By definition, qualitative interactions do not arise where treatments are innocuous. In the presence of a small amount of treatment-related harm, the harm may be quantitatively negligible among high-risk patients but sufficient to erode much (or all) of the benefit in low-risk patients (Figure 4) . The importance of risk modeling for HTE in treatments with treatment-related harm has been shown in simulation studies (49, 66) and observed empirically for carotid endarterectomy (51), stroke prevention in nonvalvular atrial fibrillation (67, 68) , and medical or mechanical reperfusion in STsegment elevation myocardial infarction (64, 69, 70) . Treatment-related harm may be reflected in the primary outcome or ascertained as a separate outcome (such as acute kidney injury, major hemorrhage [54, 71] , or serious bone fractures) (55, 72) . Risk modeling may also be appropriate for particularly burdensome interventions (for example, major lifestyle commitments [32, 73] and treatment-related costs) (74, 75) .
When several large, well-conducted RCTs of contemporary interventions are available and appropriate for pooling in individual patient meta-analysis.
Clinical trials are typically powered to detect an overall average treatment effect in a population, not to estimate effects in relevant subgroups. Very large databases are required for effect modeling, in which multiple individual covariate-by-treatment interactions are considered. The sample required to detect a subgroup effect is at least 4-fold larger than for a main effect, even under favorable conditions (that is, well-balanced subgroups and overall and subgroup effects that are similar in size), but will generally be much larger than that (23, 24) . Although a risk-modeling approach does not depend on the discovery of statistically significant covariate-by-treatment interaction terms, greater statistical power improves the precision of effect estimation across risk strata, thus improving the ability to estimate benefit-harm tradeoffs across strata. We also emphasize the need for contemporary trials because they are more likely to be relevant for contemporary clinical care. In addition, although such analyses have not been consistently successful in discovering reliable treatment effect interactions (76) , combining data is likely to lead to substantial increases in risk heterogeneity in the study population (criterion 5), increasing the likelihood of uncovering clinically important HTE (that is, on the risk difference scale) (77, 78) .
When substantial, identifiable heterogeneity of risk in the trial population is anticipated.
Risk heterogeneity depends on the presence of significant factors to predict outcome risk and differences in the distribution of these factors across the population (that is, a nonhomogeneous population). In the absence of factors that can predict outcome risk, no risk heterogeneity exists. Conversely, risk heterogeneity is highest in the presence of good discrimination (that is, a high c-statistic). Indeed, risk heterogeneity in a given population is a model-dependent property (79) . Figure 5 shows the empirical relationship between the c-statistic and the extreme-quartile risk ratio (the ratio of outcome rate in the highest risk quartile to that in the lowest risk quartile [80] ) across 32 publicly available trials (48) . Because clinical prediction models are abundant (7, 81, 82) , the predictability of trial outcomes can generally be evaluated, at least informally, from the literature. Trials with broad inclusion criteria, and thus a broad case mix, are more likely to show greater risk heterogeneity than trials with more narrowly restrictive enrollment criteria. Nevertheless, risk heterogeneity seems to be substantial even in classic efficacy trials (32, 48, 64, 70, 71) . Because individual patient metaanalyses (that is, combining trials) have even higher risk heterogeneity at the patient level, they are an ideal substrate for these analyses (77, 78) .
6. When there is strong preliminary evidence that a prediction model is clinically useful for treatment selection, or when models are in current use for treatment selection.
Most prediction models developed are not applied in clinical practice (81) . Some fields produce many new prediction models without clear purpose except as publishable analytic exercises. The development of new models should instead start from some clinical need. Thought- The curves depict the relationship between the c-statistic and EQRRthat is, the risk in the highest quartile compared with the risk in the lowest quartile-for different outcome rates across 32 trials (46) . Unsurprisingly, the degree of risk heterogeneity (as represented by the EQRR) is strongly related to the discriminatory power of the prediction model. The relationship is strongest when overall outcome rates are low. The c-statistic and EQRR both reflect how well the risk factors predict the outcome in a given population. For reference, in a trial with an outcome rate of 15%, a predictive model with a c-statistic of 0.80 is anticipated to yield an outcome rate that is 13-fold higher in the highest risk quartile than in the lowest risk quartile. When the outcome rate is lower (5%), this ratio is expected to be >20-fold for a model with similar discrimination. Patient groups with such different outcome risks are unlikely to have similar benefit-harm tradeoffs for most therapies, even though they may be included in the same trial. EQRR = extremequartile risk ratio.
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ful selection of a "risk-sensitive" decision is a crucial step in developing a useful clinical prediction model (83) . The use of a prediction model in clinical practice may be an implicit marker of a risk-sensitive decision for which clinicians sense that the balance of the benefits and burdens of a treatment decision vary across the population in a clinically meaningful way. For example, the widespread use of the CHADS 2 score (67, 68) (and its variations [84] ), the atherosclerotic cardiovascular disease score (47) , and chest pain tools (85, 86) may be considered a marker of the risk sensitivity of these decisions. Similarly, the widespread use of certain diagnostic prediction models in emergency departments to rule out rare but serious conditions (such as cervical spine fracture [87] , intracranial hemorrhage [88] , and pulmonary embolism [89] ) in lowrisk patients to reduce the harms and burdens of further diagnostic testing is a marker of the risk sensitivity of this class of decisions. Such consensually established, implicitly revealed, risk-sensitive decisions remain relatively uncommon. Moreover, randomized data are relatively scarce, and risks may change meaningfully over time.
Hence, opportunities to reexamine the risk-specific benefits (or validate predictions of benefit) in new trial data are highly valuable. 7. When the clinical variables in the proposed models are routinely available in clinical care.
The advantages of easily and reliably obtainable clinical characteristics as predictors should be obvious. Nevertheless, the literature contains many examples of models that include variables not ordinarily obtained in clinical care. For example, waist-to-hip ratio is a very strong predictor of diabetes and cardiovascular risk (90, 91) , but it is rarely ascertained in routine clinical care. Prostate volume is an important predictor of prostate cancer risk but can only be obtained by an invasive test and is therefore of questionable value for use in models (86) . By raising the burden of variable ascertainment, we lower the probability that a prediction model will be used, compared with selecting the best treatment on average. Again, because of the abundance of published risk models, well-established risk predictors can usually be ascertained from the literature before the analysis of trial data, even when internal risk models will be used to stratify the data.
Explication of Excluded Criteria
The PATH technical expert panel did not reach consensus (as defined by a mean agreement score <3) on 2 additional criteria to identify when a risk-modeling approach is likely to be of value to analyze RCT results. The SDs of the agreement scores were also relatively high (>1) for these criteria, reflecting the conflicting positions held by panelists. Both criteria are described in the following paragraphs.
When the outcome rate is lower. A low outcome rate is associated with a more asymmetrical distribution of estimated absolute benefit (on the probability scale) across individuals in a trial ( Figure 5 ). For example, when the outcome rate is 6% overall and the c-statistic is 0.80, the average outcome rate in the quartile of patients at lowest risk is anticipated to be approximately 1% (48) . Although benefit is limited by a floor effect-it is impossible to decrease outcome risk to less than 0 -treatment-related harms can still be substantial. The high-risk group (that is, the highest risk quartile) in these low-outcome trials frequently has outcome rates more than 10-fold those found in the low-risk group and may account for most of the benefit in the trial (Figure 4, right) . These skewed distributions follow from the logistic regression scale (log odds) and Cox regression scale (log hazard [48] ). This makes the average risk (and treatment benefit) misleading even for typical patients enrolled in the trial (48, 92) . Nevertheless, the expert panelists disagreed about whether a low outcome rate was a useful criterion to identify worthwhile target trials for risk modeling. Outcome rate is estimated from empirical data with unavoidable uncertainty and unknown generalizability in other populations, which may have higher outcome rates.
When the 2 treatments are clinically very different (for example, medicine vs. surgery).
Several treatment selection models have been successfully developed on RCT data comparing treatments that have substantially different mechanisms of action. For example, well-known prediction models have been developed on randomized data to disaggregate treatmentfavorable from treatment-unfavorable patients for carotid endarterectomy versus medical therapy for symptomatic carotid stenosis (51), or for percutaneous coronary intervention versus coronary artery bypass grafting for nonacute coronary artery disease (93) . Nevertheless, the technical expert panel disagreed on whether this criterion was a reliable marker of worthwhile opportunities for risk modeling. Indeed, when interventions in alternative trial groups differ substantially, individual variables may interact with treatment, making an effect-modeling approach more advantageous than a risk-modeling approach, such as in the SYNTAX (Synergy Between Percutaneous Coronary Intervention With Taxus and Cardiac Surgery) score II model for coronary artery bypass grafting versus percutaneous coronary intervention (93) .
JUSTIFICATION OF GUIDANCE ON RISK-MODELING STRATEGIES TO IDENTIFY HTE
The following criteria describe best methodological practices in the conduct of risk-modeling approaches to identify HTE ( Figure 3 of the PATH Statement [26] ). The motivations regarding these statements are elaborated, including reservations, considerations, and caveats. When outcome risk is described using a multivariable model, the control event rate will vary substantially across risk strata of an RCT. This rate may vary between 5-and even 20-fold across risk strata in trial populations (48, 94) . The control event rate is a mathematical determinant of the treatment effect, regardless of what scale is used to measure treatment effect ( Table 1) . Because typical treatment effect metrics are different (nonlinearly related) contrasts of the same 2 quantities (control and treatment event rates), when the control event rate changes across subgroups, the treatment effect can remain constant on (at most) 1 scale. In particular, large changes in the control event rate almost always lead to substantial changes in the most clinically relevant scale of effect measure, the absolute risk difference (4, 95). Thus, the widespread assumption that benefit-harm tradeoffs are usually similar for patients meeting trial enrollment criteria is demonstrably false and may be harmfully misleading (4) . Indeed, the assumption of a constant relative treatment effect across groups of patients that vary dramatically in their control event rateespecially in the presence of treatment-related harmneeds to be carefully examined. Presenting overall trial results without showing how the treatment effect varies across risk strata-and particularly whether changes in the risk difference are clinically important across risk strata-may be considered a form of underreporting of trial results (6).
2. Predictive approaches to HTE require close integration of clinical and statistical reasoning and expertise.
The optimum treatment selection model will generally be grossly underdetermined by the available data, particularly from a single RCT and when multiple risk markers that may be important are considered. Thus, it is generally not possible to use agnostic, datadriven approaches alone for variable and model selection when analyzing clinical trials for HTE. Prediction of treatment effect at the individual patient level may be very sensitive to arbitrarily determined model-building choices that define the reference class (that is, subgrouping) scheme (96, 97) . In theory, these issues asymptotically diminish as databases become infinitely large, but clinical reasoning remains critical to the process of variable selection and model specification in the identification of a clinically plausible, clinically useful, and clinically usable model from the limited data sources that are generally available. Similarly, given the specialized expertise needed for prediction modeling, clinical investigators should generally not proceed without experienced statistical collaborators. Thus, realizing the goal of predictive HTE analysis requires close partnership between clinical and methodological experts.
Identify or Develop a Model
3. When available, apply a high-quality, externally developed, compatible risk model to stratify trial results.
For major clinical trials (those that assess a treatment's effect on mortality, major morbidity, or other key clinical outcomes), risk-based analysis of HTE can often be done using an externally developed tool. Prediction models are available to predict overall risk for most major conditions and their complications (7) . Nevertheless, differences in populations or variable definitions may render published models incompatible with completed RCTs. Investigators may also choose to develop a new model using data from a related observational study or clinical trial. An external model is more relevant if the eligibility criteria for the derivation cohort align with-or are even broader than-those in the target trial. Ideally, definitions of predictor and outcome variables should be similar to those available in the RCT. An externally derived model enables translation into practice, especially when well-validated and clinically accepted models compatible with the RCT are available.
4. When a high-quality, externally developed model is unavailable, consider developing a model using the entire trial population to stratify trial results; avoid modeling on the control group only.
When high-quality, externally developed models are not available, internally derived (or endogenous) models can be used. Guidance on good prediction modeling practice should be followed-for example, many events per independent variable and prespecified, a priori selection of risk variables based on prior literature (98, 99) . Models derived directly on RCT data may provide internally valid estimates of treatment effect within risk strata. One approach is to ignore treatment assignment in developing the model (100) . The risk model defines the reference class or subgrouping scheme (4); a second step then estimates treatment effects across risk strata. Separating the variable selection and model specification process from treatment effect estimation minimizes some of the biases (such as "testimation bias" [98] ) that complicate effect modeling. Alternatively, some have recommended that only the control group be used to model risk (101) because this ostensibly generates the best estimate of the control event rate. However, modeling on the control group only can induce differential model fit on the 2 trial groups, biasing treatment effect estimates across risk strata and generally exaggerating HTE (49, 100, 102) ; various cross-validation techniques have been proposed to address this bias even for modeling on only the control group (103) . Concerns about differential fit between groups from endogenously derived models may also apply when randomization is unbalanced (for example, 1:2 or 1:3 randomization) or when treatment effects are very large, such that the control group has many more events than the treatment group. When imbalance in events is caused by very large treatment effects, risk-based HTE may be less clinically relevant (Figure 3) . Potential approaches to modeling on trials RESEARCH AND REPORTING METHODS
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with imbalanced randomization or strong treatment effects should be evaluated in future research ( Table 2) .
When developing new risk models or updating externally developed risk models, specify the analytic data plan before examining trial data and follow guidance for best practices for prediction model development.
Although not the focus of the PATH Statement, the development of new risk models or updating of externally developed models is supported by existing guidance (98, 99, 104) . In particular, the TRIPOD (Transparent Reporting of a multivariable prediction model for Individual Prognosis Or Diagnosis) explanation and elaboration document (104) offers detailed, referenced guidance (with published exemplars) on how to design, conduct, and analyze prediction model studies with a view to limiting risk of bias and maximizing the clinical usefulness of the model. TRIPOD indicates that continuous predictors should ideally be kept as continuous (and examined for linear or nonlinear relations with the outcome). This best practice of modeling continuous variables continuously, or modeling risk continuously, does not necessarily proscribe the common practice of showing clinical trial data to readers in subgroups, (which is part of the guidance under Apply the Model, and Report Results). The TRIPOD explanation and elaboration document (104) also provides a good discussion of the considerations for handling missingness for clinical prediction models, which are relevant here. When important risk factors are missing on some patients, analyses should apply techniques, including multiple imputation when appropriate, to avoid excluding patients who were randomly assigned to a group. Alternative approaches for subgroup identification in the presence of missing variables should be investigated in future research ( Table 2 ). The PROGRESS (Prognosis Research Strategy) series of articles (105) (106) (107) (108) and several textbooks also offer guidance on the optimal development of clinical prediction models (98, 99) .
Because adequate power for HTE analysis might best be achieved by combining multiple randomized trials, prediction modeling guidance should be complemented in these cases by guidance for best practices for individual patient meta-analysis (109) . In particular, inclusion of study-specific intercepts to account for unexplained risk heterogeneity is recommended (110, 111) . Similarly, study-specific effects should be accounted for in analyzing treatment effects. Alternative meta-analytic approaches are discussed in the literature and are beyond the scope of this guidance (112, 113) .
Apply the Model, and Report Results
Report metrics for model performance for outcome risk prediction on the RCT, including measures of discrimination and calibration (when appropriate).
7. Report distribution of predicted risk (or the risk score) in each group of the trial and in the overall study population.
8. Report outcome rates and both relative and absolute risk reduction across risk strata. 9 . When there are important treatment-related harms, these harms should be reported in each risk stratum to support stratum-specific evaluation of benefitharm tradeoffs.
Consistent with the TRIPOD Statement, we recommend that measures of discrimination and calibration Table 2 
. A Meta-research Agenda for Predictive Approaches to HTE
High-priority research needs
Better understand the value of HTE methods through empirical analyses across a wider range of clinical domains. Determine optimal approaches to penalization/regularization in effect modeling to mitigate the risks of overfitting, or other methods that permit the exploration of plausible hypotheses of effect modification on the relative scale while strongly protecting against false-positive findings. Determine optimal methods to simultaneously predict multiple risk dimensions (e.g., risk for the primary outcome vs. risk for treatment-related harm) or optimal approaches to combine models predicting these outcome risks for improved benefit-harm discrimination. Determine the optimal measures to evaluate models intended to predict treatment benefit. Identify heuristics or general principles to judge the adequacy of sample sizes for predictive analytic approaches to HTE, particularly for treatment effect modeling. Determine optimal methods to validate, recalibrate, or update models predicting treatment effect in the absence of new randomized trials.
Other research needs
Determine optimal methods to combine predictive HTE analyses with methods that permit the estimation of direct treatment effects or adherence-adjusted effects in the presence of dropout, loss to follow-up, poor adherence, and treatment switching. Identify the appropriate clinical contexts for which modeling multiple dimensions of risks (e.g., risk for the primary outcome, risk for treatment-related harm, and risk for an important competing outcome) is important and feasible for adequate disaggregation of benefit-harm tradeoffs. Determine methods to analyze trials with multiple important outcomes, or outcomes where differences in treatment effect may be related to choice of follow-up time. Better understand the effect of different missingness mechanisms, and develop principled methods for dealing with missing data in the context of subgroup identification. Determine methods to permit models predicting treatment effect to cope with missing data in clinical practice. Determine optimal methods for modeling the functional form of the risk-by-treatment interaction to translate risk-stratified results from trials into continuous treatment effect predictions for clinical application.
be presented whether an externally or internally derived model is applied (recommendation 6 in Figure 3 of the PATH Statement [26] ). However, these conventional measures of model performance should not be confused with discrimination and calibration of predicted benefit (see Special Considerations for Evaluating Models That Predict Benefit). We also note that point scores, such as TIMI (114), CHA 2 DS 2 -VASc (84), and ABCD2 (115), may be useful for trial risk stratification but do not yield predictions for calibration. Although its importance was highlighted 2 decades ago (94) , reporting the distribution of baseline risk is rarely done (recommendation 7 in Figure 3 of the PATH Statement [26] ). Thus, assessing the degree of baseline risk heterogeneity is generally impossible in most published clinical trials. Risk reporting should allow readers to assess the full distribution of risk in the study population, either graphically or through information on the mean, SD, median, and interquantile ranges. The precise approach for presentation is not important, as long as it allows the reader to understand the distribution of predicted baseline risk (or the risk score of a risk index) in the study population. The "Table 1" of a clinical trial report (which conventionally includes attributes for participants in each study group) should also include the population mean and median predicted baseline risk (or risk score) with measures of variability, as well as additional information on the population distribution of risk if skewness is substantial (such as quartiles or percentiles, a histogram, or a box plot). If the study population is largely homogeneous with regard to overall risk, the reader will know that generalizing the study results to populations with substantially different risk would be speculative. If heterogeneity is substantial in the study population, reviewers will know that conducting a risk-stratified analysis is particularly important.
As an initial step, we recommend grouping patients using quantiles (such as quartiles) for reporting purposes and showing and estimating treatment effects separately in these groups (for example, dividing patients into equalsized quarters) (recommendation 8 in Figure 3 of the PATH Statement [26] ). Reporting treatment effects across strata is important because it illustrates how the absolute risk difference varies across the study population, regardless of whether the relative effect is constant (Figure 4 [right] is an example). In addition, it permits evaluation of the assumption of a constant relative effect across risk strata (see recommendation 10 in Figure 3 of the PATH Statement [26] and explanation in discussion under recommendation 10 here). Alternatively, treatment effects can be presented by continuous risk, as seen in Figure 2 , rather than by quantiles (which are sample-dependent). As discussed earlier, examining variation in relative treatment effects may be particularly important when even a small amount of treatment-related harm exists (3, 66) . In time-to-event analysis, treatment effects should be analyzed and reported by cumulative incidence curves. Relative treatment effect estimates can be summarized by hazard ratios over a clinically meaningful time horizon (or several such horizons). Absolute treatment effect esti-mates can be summarized by cumulative incidences at a clinically meaningful time point (or several such points). In reporting risk-stratified results, authors provide readers with the information needed to easily determine the amount of variation in risk difference or number needed to treat and relative effects. These stratum-specific results can provide a rough guide for clinical interpretation, which can be further refined for clinical implementation by continuous modeling (recommendation 3 in Figure 4 of the PATH Statement [26] ).
From a decision analytic perspective, the clinical value of a prediction model is determined by its ability to distribute patients by their absolute treatment effect across an important decision threshold. This threshold depends on the burdens of treatment, which depend on treatment harms and costs and patient values and preferences. However, even apart from these values and preferences (which are inherently patient-specific), treatment burden may differ substantially across patient subgroups. Because patients in different risk strata vary in many clinically important characteristics, subgroups stratified by risk for the primary outcome cannot be assumed to have similar rates of treatment-related harms. For example, patients with atrial fibrillation who have higher CHADS 2 scores (indicating higher stroke risk and greater potential benefit from anticoagulation) also have substantially higher risk for bleeding (72) . Patients with higher risk for stroke recurrence, according to a recurrence risk score, may benefit more from pioglitazone but also have higher risk for pioglitazone-related bone fracture (65) . Because of the potential correlation between these 2 risk dimensions (that is, between risk for the primary outcome and risk for treatment-related harm), event rates for these harms should be presented at a level of disaggregation that is congruent with that of the primary outcome so that readers can determine benefit-harm tradeoffs within risk strata (recommendation 9 in Figure 3 of the PATH Statement [26] ).
Risk modeling may be most useful when predictors of risk for the primary outcome and benefits of therapy are poorly (or negatively) correlated with risk for treatment-related harm. This will maximize heterogeneity in the benefit-harm tradeoffs across risk strata, increasing the decisional value of the risk model. Although several investigators have sought to arithmetically combine separate prediction models for outcome risk and treatment-related harm to stratify trial results by benefit-harm tradeoff (51, 69, 71) , this approach can be very sensitive to miscalibration of the 2 models (which may compound miscalibration of benefit-harm tradeoffs). The best approach to modeling benefits and harms simultaneously is beyond the scope of these recommendations and is an important topic for future research ( Table 2) .
To test the consistency of the relative treatment effect across prognostic risk, a continuous measure of risk (for example, the logit of risk) may be used in an interaction term with treatment group indicator.
Although testing for a statistical interaction between subgroups is recommended to determine HTE, when the outcome rates vary substantially across strata, the risk difference can also be assumed to vary ( Table 1 RESEARCH AND REPORTING METHODS
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and Figure 4 ). Thus, even though the absolute scale is the most relevant clinically, null hypothesis testing for HTE across risk strata on the risk difference scale is generally not useful because a nonsignificant result is far more likely to reflect low power than true consistency of effects on the risk difference scale. Statistically testing a risk-by-treatment interaction on the relative scale (for example, whether the linear predictor of risk interacts with treatment) provides information on whether a constant relative treatment effect may be a reasonable approximation with which to estimate a risk-specific ("individualized") treatment effect. Nevertheless, the presence or absence of a statistically significant result should not be conflated with the clinical significance of HTE (which should always be evaluated on the risk difference scale). In a risk-by-treatment interaction test, using a continuous measure of risk (such as the logit of risk) typically provides superior power compared with testing for effect differences across distinct risk groups (Figure 4, middle right) (116) . A visual (nonparametric) exploration of how the relative effect varies across values of outcome risk may ensure the appropriateness of linear effect modification. Testing for a nonlinear interaction between risk and treatment (for example, using the logit of risk in a quadratic term, or with another flexible nonlinear shape [117, 118] ) may also be useful. However, such an interaction test may be poorly powered to detect deviations from linearity, particularly when only a single trial with a limited number of events is the substrate for modeling. Moreover, once the existence of an overall treatment effect is established, determining the risk-specific treatment effect should be considered an estimation problem (rather than a hypothesis-testing problem). Flexibly modeling the treatment effect across risk strata, or simply reporting the effects across subgroups defined by quantiles (such as quartiles), provides useful information regardless of the P value of the interaction terms testing effect modification on the relative scale. Standard errors across levels of risk can be estimated through a proportional interactions model (119, 120) . Most important, the presence or absence of a statistically significant treatment interaction term (on the relative scale) should not be conflated with the presence or absence of clinically important HTE (on the absolute scale) (see discussion of recommendation 1 under Justification of Caveats and Considerations Before Moving to Clinical Practice, below).
JUSTIFICATION OF CAVEATS AND CONSIDERATIONS BEFORE MOVING TO CLINICAL PRACTICE
The following considerations relate to the translation of findings from predictive approaches to HTE analyses into clinical practice (Figure 4 in the PATH Statement [26] ). Clinical translation of these analyses is a complex topic that includes many issues, and a detailed discussion of these challenges is beyond the scope of this project, where we focus on analysis and reporting of RCT findings. However, these analytic considerations are priorities for facilitating model translation into clinical practice.
Clinical interpretation of HTE should stress differences in the absolute treatment effects across risk groups: The statistical significance of effect modification on the relative scale should not be conflated with the clinical significance of absolute treatment effect estimates.
The clinical significance of HTE should generally be discussed with reference to the absolute scale, whereas a relative scale (such as odds ratio or hazard ratio) is typically appropriate for null hypothesis testing in HTE analyses. Investigators should consider reporting results in ways that facilitate clinical interpretation of how treatment decisions might be changed with use of the risk model (for example, number of patients treated or number of events avoided with vs. without model use) and should consider decision analytic approaches for evaluation (58, 121) . Table 3 illustrates how results can be presented in a simple way that facilitates understanding of the clinical relevance of risk modeling. Presentation of important treatment-related harms should also permit within-stratum evaluation of absolute effects.
External validation and calibration of risk prediction is important for translation of risk-specific treatment effects into clinical practice.
Although internally derived (or endogenous) prognostic models can provide reliable internally valid estimates of treatment effects within trial risk strata, implementation of an externally valid prognostic model is necessary for translation into practice (107). Finding clinically important HTE across risk strata within a trial with an endogenous model provides an important impetus for developing and implementing an externally valid prognostic model. Of note, external validity is a general concern for RCT results and their subgroup analyses and is not confined to results subgrouped using prediction models (122) .
Clinical implementation may be supported by translating multivariable risk-based subgroup analysis into models yielding continuous treatment effect predictions to avoid artifactual discontinuities in estimation at the quantile boundary of an outcome risk group.
In presenting HTE analyses of clinical trial results, it is customary to categorize patients into subgroups. Here, we have recommended presenting results in risk strata. Nevertheless, dividing patients into discrete groups based on values of a continuous measure has some disadvantages (123) . Categorization into risk groups suggests that risk and treatment effects are homogeneous within groups and leads to a potentially misleading "step function" in estimation of risk or treatment effect. With such an approach, for example, a very small change in risk at the boundary of a group defined by a quantile can lead to a very large change in anticipated benefit. In addition, quantiles have specific disadvantages in that they are sample-driven cut points, which leads to difficulties in comparing results across studies (124) and may also obscure problems with model calibration. For example, use of an internally developed risk model and use of the Framingham model to stratify patients in the DPP trial seemed to yield near-identical results (32, 33) . However, if the trial population had been divided into groups based on predicted risk thresholds (as it would be in clinical practice), risk groups defined by the Framingham model would have shown that the Framingham model was poorly calibrated to the DPP trial population. Thus, although trial results displayed by risk strata are frequently sufficient to evaluate the clinical importance of risk-based HTE, clinical implementation may be supported by translating multivariable risk-based subgroup analysis into models yielding continuous predictions of outcome risks with and without therapy (Figure 1, legend) .
TREATMENT EFFECT MODELING TO IDENTIFY HTE Considerations Regarding the Inclusion of Rigorously Selected Effect Modifiers
Conventional 1-variable-at-a-time subgroup analyses are known to have low credibility due to noisy data (very low power for interactions), weak theory (little prior knowledge about effect modification), and multiplicity (4) . Including relative effect modifiers as interaction terms within a prediction model engenders the same concerns ( Figure 5 in the PATH Statement [26] ).
Although relative effect modifiers are difficult to reliably identify, they are highly influential on individual patient predictions of benefit (122) . Including spurious false-positive interaction terms in models that predict treatment benefit can mistarget therapies, and excluding true interaction terms limits the usefulness of prediction by substantially lowering discrimination of patients who benefit from those who do not (30). Whether to include a treatment effect interaction term in a prediction model is a fraught and consequential decision; the PATH technical expert panel accordingly recommends a cautious approach. We restrict our recommendations to the unusual situation where highly credible effect modifiers have been identified, and we otherwise offer caveats and considerations for more data-driven approaches.
When highly credible relative effect modifiers have been identified, they should be incorporated into prediction models using multiplicative treatment-bycovariate interaction terms.
A. Credibility should be evaluated using rigorous multidimensional criteria and should not rely solely on statistical criteria (such as P value thresholds).
Important efforts have been made to establish criteria that might identify highly credible subgroup anal-yses (9, 19, 125) . A newly proposed tool (ICEMAN [Instrument for assessing the Credibility of Effect Modification ANalyses] [125] ) is based on 5 criteria to evaluate credibility of effect modification. Four of these criteria are related to prespecification and markers of the "prior probability" or plausibility of effect modification: presence of prior evidence, prespecification of a few primary subgroup analyses, prespecification of the anticipated directionality of effect modification, and full specification of cut points when thresholds are used for continuous variables. The fifth criterion (a low P value) is a measure of the statistical strength of the interaction effect in the data being analyzed. The PATH group endorses the rigorous and multidimensional approach recommended in ICEMAN to identify highly credible interaction terms. Examples of highly credible effect modifiers include symptom onset to treatment time for thrombolytic therapy for acute myocardial infarction or acute ischemic stroke (126, 127) , gender as a modifier of the effect of thiazolidinediones on fracture risk (128 -130) , and urinary protein excretion as a modifier of the effect of angiotensin-converting enzyme inhibition on the progression of chronic kidney disease (77, 131) .
In the analysis of trial data, identification of credible interaction terms can be facilitated by explicitly distinguishing subgroup analyses that are intended to be confirmatory (hypothesis-testing analyses that are well motivated by prior evidence and intended to produce clinically actionable results) from secondary (exploratory) subgroup analyses (done to inform future research) (7, 8) . Because in any given clinical trial prior information regarding effect modification is typically limited, subgroup analyses will frequently be exclusively exploratory and therefore not yield any covariateby-treatment interaction effects appropriate for inclusion in prediction models intended to inform clinical care.
Prespecification of primary subgroups should include explicit definitions and categories of the subgroup variables, including cutoff thresholds for continuous or ordinal variables where these are used and the anticipated direction of effect modification. When primary subgroup analyses are few in number, fully prespecified, hypothesis-driven, and statistically robust (that is, based on multiplicative interactions), subgroups can produce evidence regarding factors that influence the benefit of treatment that might then be carried forward into models to yield clinically actionable predictions.
Although only primary (confirmatory) subgroup analyses are relevant for clinical decisions and the predictive HTE analyses we address here, we acknowledge the importance of secondary subgroup analyses to explore more uncertain or unexpected relationships between individual patient attributes and treatment effects; such analyses are appropriate to generate hypotheses, which can then be tested (and usually disproved [23, 25, 132, 133] ) in future studies.
Because P values (or other statistical criteria) in general are influential in how subgroup analyses are interpreted (and are included in ICEMAN criteria) and because interaction effects are poorly estimated in tri-RESEARCH AND REPORTING METHODS PATH Statement Explanation and Elaboration als of conventional size (even when these are pooled), treatment interaction terms selected for inclusion are likely to overestimate the true interaction effects (that is, from overfitting) (4, 30, 134) . Therefore, even when only highly credible interaction terms are included, we recommend model-building procedures that take into account model complexity (that is, approaches using regularization or penalization) whenever interactions are included (recommendation 3 in Figure 5 of the PATH Statement [26] ).
Caveats and Considerations for Data-Driven Effect Modeling
Emerging "data-driven" methods-proposed to develop effect models on trial data when prior information on effect modifiers is limited-are a promising area of research (28) , but the technical expert panel believed them to be at too formative a stage to offer recommendations. A systematic scoping review (135) was done in an effort to characterize this rapidly evolving literature, and it revealed future research opportunities. Table 4 summarizes at a high level the key features of the differing approaches. In addition to risk and effect modeling, the scoping review identified methods collectively described as optimal treatment rules that use combinations of relative effect modifiers to classify patients into treatment-favorable and treatment-unfavorable categories-that is, based only on the sign of the effect. Because these are classification rather than prediction methods, we do not discuss them in our guidance but direct interested readers to the literature on these approaches (136 -146) . A key feature of many of the procedures for predictive analyses (and particularly effect modeling) is that they separate the variable selection procedure in building a model that defines subgroups (or reference class scheme) from the estimation of treatment effects, thereby avoiding testimation bias (98, 147, 148) . Alternatively, various methods of penalization or regularization to reduce the likelihood of overfitting have been proposed and tested (149) . Although the PATH technical expert panel did not articulate a full set of methodological best practices for treatment effect modeling given more limited practical experience (compared with risk modeling), we offer caveats and considerations for this type of predictive HTE analysis (and their justifications) in the following paragraphs.
Avoid 1-variable-at-a-time null hypothesis testing or stepwise selection (such as backward selection or forward selection) strategies to select single-variable relative effect modifiers.
One-variable-at-a-time null hypothesis testing will preferentially select effects that are overestimated within the sample database (that is, type I error and testimation bias). Including treatment interaction terms in models predicting benefit generally requires reliable prior information regarding relative effect modifiers. Interaction terms for well-established treatment effect modifiers should be included in the prediction model, regardless of the statistical significance of the interaction (recommendation 1 in Figure 5 of the PATH Statement [26] ). When multiple relative effect modifiers are hypothesized to be of potential importance in determining treatment effects, the value of including these interactions can be assessed simultaneously by a single overall test, limiting the opportunity for type I error and testimation bias (104). To increase the power of this test, the number of treatment effect interactions included should be limited (104). Investigators should use clinical considerations and should also consider examining associations between candidate effect modifiers to reduce the number of interactions assessed within the overall test. A null result on the overall test for interaction suggests that an effect-modeling approach (that is, including interaction terms) will not add substantially to a risk-modeling approach.
3. Avoid the use of regression methods that do not take into account model complexity when estimating coefficients (for example, "conventional" unpenalized maximum-likelihood regression) when 1 or more treatment-by-covariate interaction terms are included in a treatment effect model.
Although no consensus exists on the optimal approach for including relative effect modifiers in a prediction model (that is, an "effect model"), conventional regression techniques will generally result in overfitting. Penalized estimation (such as with LASSO [least absolute shrinkage and selection operator] regression or ridge regression, elastic net regularization regression, Bayesian penalization, and other non-regression-based methods discussed earlier) at least partially addresses the tendency to overfit benefit predictions. The optimal ap- 
Approach Description
Risk-modeling approaches (7, 48, 66, 100, 119, 120, 122, (151) (152) (153) (154) Using a multivariable risk model developed blinded to treatment effect, analyze the relationship between baseline risk and treatment effect on the relative and absolute scales. Whereas treatment effect modification on the relative scale across different levels of baseline risk is considered, treatment effect modification on the relative scale for individual risk factors is not. Treatment effect-modeling approaches (122, 147-150, 154-161) Subgroup identification (2-step process) (147, 148, 155) Individualized treatment effects (1-step process) (122, 149, 154, (156) (157) (158) Use both the main effects of risk factors and interaction effects with treatment assignment (on the relative scale) to estimate more individualized treatment effects. They can be used either for defining patient subgroups with similar expected treatment effects or for predicting individualized treatment effects on the absolute scale for future patients.
Optimal treatment regimens (136) (137) (138) (139) (140) (141) (142) (143) (144) (145) (146) Classify patients into those who benefit from treatment (positive individualized treatment effect) and those who do not (negative individualized treatment effect) through identification of modifiers of treatment effects on the relative scale. HTE = heterogeneity of treatment effects.
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Annals.org Annals of Internal Medicine proach to penalization for effect modeling is a subject of current research, but avoiding overfitting for benefit prediction is much more difficult than avoiding overfitting for outcome prediction (Figure 6) . Alternatively, 2-stage methods relying on different data sets (or subsets) for variable and model selection for determining the subgrouping (that is, reference class) scheme and for treatment effect estimation can also avoid or mitigate testimation bias. 
Benefit Calibration
These data are box plots of predicted and observed hypothetical examples of event rates divided by quartiles of predicted risk in the control and treatment groups of a hypothetical randomized controlled trial (500 simulations) (top). These rates seem to demonstrate appropriate model calibration. However, examining the same data for predicted and observed benefit (differences in event rates) by quarters of predicted benefit (bottom) reveals very poor model calibration at the extreme quarters. This poor calibration occurs because miscalibration for the risk difference includes error from both control and treatment groups and because the scale of risk difference is much smaller than that of outcome risk. These data were generated from a simulation of a prediction model that included 12 treatment effect interactions, 6 of which represented true interactions. The boxes represent, in line with the Tukey definition, the 25% quantile to the 75% quantile (with the median shown). The lower and upper whiskers include the most extreme observations within the range of 1.5 times the interquartile range, from the 25% and 75% quantiles, respectively.
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4. Avoid evaluating models that predict treatment benefit using only conventional metrics for outcome prediction (for example, based on discrimination and calibration of outcome risk prediction).
The performance of models intended to predict benefit should be evaluated for the prediction of benefit, not for their ability to predict outcome risk. Calibration for outcome risk can be seriously misleading in evaluation of models that purport to predict treatment benefit ( Figure 6) . The discrepancy arises because benefit miscalibration compounds the error in risk estimation in the control and treatment groups and magnifies this error (that is, the scale of risk difference is typically much smaller than that of outcome rate). Evaluation methods that pertain to models intended for treatment selection or benefit prediction are discussed further in the following section.
SPECIAL CONSIDERATIONS FOR EVALUATING MODELS THAT PREDICT BENEFIT
The statistical performance of prediction models is typically decomposed into measures of calibration ("Do x of 100 patients with a predicted risk of x% actually have the outcome?") and discrimination ("What is the probability that patients with the outcome have a higher predicted risk than those without the outcome?"). Evaluating a prediction model intended to predict treatment effect using these usual metrics related to outcome risk prediction (such as the c-statistic) does not provide information on how well the model performs for predicting benefit and informing treatment decisions. Efforts to develop measures to assess model accuracy for predicting benefit (in particular, evaluating measures of discrimination for benefit) are hampered by the fundamental problem of causal inference for the individual. That is, individual patient treatment effects are inherently unobservable because only 1 of the possible outcomes is observed for each patient (the actual outcome they experienced under the treatment to which they were randomly assigned and not the counterfactual outcome under the alternative) (162) .
For example, for "predictive" biomarkers (factors that can aid in treatment selection), some statisticians have suggested evaluating performance by the sensitivity and specificity of the biomarker for benefit rather than risk (163) . However, these quantities can be estimated only under strong, unverifiable assumptions about the joint distribution of observed and unobserved outcomes so that each patient can be assigned to a treatment response (benefit [bad outcome without treatment and good outcome with treatment {1,0}], neutral [good or bad outcome regardless of treatment {0,0 or 1,1}], or harm [good outcome without treatment and bad outcome with treatment {0,1}]) (164) . For example, 1 proposed method assumes that no participants are harmed by treatment (165) ; others assume that, conditional on a set of covariates, the potential outcomes with and without treatment are independent (150, 166) . Without such assumptions, we can focus only on a mo-del's ability to predict outcome risk in 1 group of a trial or the other, rather than the model's ability to predict benefit (the difference in outcome across groups) (164, 167) .
Because counterfactual outcomes are unobservable at the individual patient level, evaluating benefit prediction requires some form of stratification of patients into groups with similar predicted benefit. The smallest possible strata are pairs of matched patients. The c-statistic, commonly used to measure discrimination in outcome risk models, has recently been adapted to evaluate treatment effect prediction (150) . To do this evaluation, 2 patients discordant on treatment assignment are matched according to their predicted benefit (that is, the absolute difference in their outcome risk with and without therapy). These matched pairs of patients with a similar "propensity for benefit" can then be classified into the following 3 benefit categories according to their "observed benefit" based on a comparison of outcomes in the control and treated patients: benefit (1,0), neutral (1,1 or 0,0), or harm (0,1). The c-statistic assesses how well the model discriminates pairs of patients on the basis of this trinary "outcome." Again, the definition of "observed benefit" assumes that the potential outcomes with the 2 therapies are independent within each patient. Because the potential outcomes within each patient are presumably dependent to some (unknowable) degree, the "observed benefit" contains more randomness than the actual (unobservable) treatment benefit for each individual patient. This leads to conservative estimates of the c-statistic.
The usefulness of a model depends on its ability not only to accurately predict within-strata treatment effect but also to improve decisions. Of course, the ultimate test of a predictive approach is to compare decisions (or outcomes) in settings that use such individualized predictions to guide care in an experiment (168) . Lamentably, this is seldom done; well-controlled trials of predictive tools are rare, and more are needed. However, even in the absence of a randomized trial, methods have been developed to assess the potential effect of models on clinical decision making. Evaluations of clinical usefulness depend on model performance relative to a specific decision threshold-that is, the absolute risk difference that perfectly balances the burdens, harms, and costs of therapy. Decision curve analysis (59) has been proposed to evaluate the clinical usefulness of prediction models in decision making. Decision curve analysis examines the net benefit across multiple decision thresholds, where each threshold is used to simultaneously determine allocation to a particular treatment strategy and mathematically derive a utility weight of benefits versus harms (implicitly revealed by the selection of that threshold). The approach has also been adapted to evaluate the potential effect of prediction of treatment benefit on decision making compared with the default best overall strategy (that is, treat all or treat none) (121) .
Because identifying the correct treatment for any given individual is impossible (except, with assumptions, in n-of-1 trials [27, 169] ), all of these methods
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RESEARCH AND REPORTING METHODS evaluate evidence personalization indirectly by evaluating whether a particular prediction-decision strategy optimizes benefits for a population (58)-which occurs when treatments are optimized for each individual.
LIMITATIONS OF THE PATH STATEMENT
We note several limitations of the PATH Statement. The guidance here is intended only for binary or timeto-event models, which account for most large, phase 3 clinical trials (170 -173) . Much of the guidance would nevertheless pertain also to continuous outcomes. The complexities of HTE analyses for increasingly common longitudinal data involving interaction with time are not discussed. Further, we focus on treatments where a decision is made at a particular point in time (corresponding to the trial baseline) rather than dynamic treatment regimens where treatment decisions may be continually revisited. We also focus on subgroup identification and treatment effect estimation rather than on HTE analyses to inform trial design. The statement also does not provide advice about performing n-of-1-or multiperson n-of-1-trials, which some consider the only means of estimating "person-level" treatment effects. We anticipate that observational studies will play an increasingly important role in studying both treatment effects and HTE, but the PATH Statement does not address HTE in observational studies (except to stress that methods of debiasing treatment comparisons to support HTE are a research priority [ Table 2 ]). Although each of the approaches we describe is consistent with the broad goal of evidence personalization, the methods are sufficiently distinct to be beyond the scope of this statement. Notwithstanding the limitations, we emphasize that the PATH Statement applies to the comparison of treatments as well as the comparison of treatment versus no treatment.
An additional limitation of the PATH Statement is that it does not address the topic of the best estimand for predictive HTE analyses and how best to cope with postrandomization events, including dropout, nonadherence, treatment switching, and loss to follow-up. These issues have received considerable attention in the methodological and regulatory literature, particularly since the National Research Council expert panel report on prevention and treatment of missing data in clinical trials (174, 175) highlighted the need to clearly define objectives and estimands, and since the subsequent ICH E9(R1) draft addendum (176). We direct readers to recent literature on this topic (177) (178) (179) . In general, the primary analysis of most trials is often an intention-to-treat analysis. However, other contrasts are also of clinical import and interest. In particular, the direct causal effect of treatment (that is, the effect if a patient adheres to treatment, estimated with a per protocol or adherence-adjusted analysis [180 -184] ) is often considered the most appropriate estimand for shared decision making in the individual patient. However, as with observational studies, estimating the direct treatment effect can be done only with methods based on unverifiable assumptions; misspecifying a model predicting nonadherence (or using an instrumental variable approach when causes of nonadherence or dropout are complex) can lead to biased estimates of treatment effects. An intention-to-treat analysis is generally believed to yield an unbiased estimate of the treatment policy, although this may be less appropriate for shared decision making. More research is needed regarding optimal ways to combine predictive HTE approaches with approaches that estimate direct treatment or adherence-adjusted effects.
DISCUSSION
The PATH Statement comprises 4 sets of guidance on the conduct of predictive HTE analyses. The purpose of the explanation and elaboration document is to explain the rationale and support for these guidance statements and to detail caveats or reservations where applicable.
The goal of predictive HTE analysis is prediction of treatment effect to support decision making in each patient (8, 185) . Developers of the PATH Statement recognize the inherent difficulties and fundamental limitations of using group data to estimate treatment effects in individuals and have enumerated some of these challenges (26) . As more deeply explored in this explanation and elaboration document, there remain substantial barriers to a full understanding of the potential of predictive HTE approaches (186) . Table 2 outlines some outstanding research questions related to methodological issues raised in the development of the PATH Statement. Stronger methodological and evidentiary standards will need to be established to ensure that incorporating these methods does not cause more harm than benefit. We also need research to better integrate clinical prediction into practice (187) , to understand how to individualize clinical practice guidelines, to establish or extend reporting guidelines (188) , to establish new models of data ownership to facilitate individual-level meta-analyses (189) , and to reengineer the clinical research infrastructure to support substantially larger, clinically integrated trials that are sufficiently powered to determine HTE (or to develop our ability to predict when observational data are likely to be sufficiently debiased for reliable HTE determination) (190) . Many recent and ongoing organizational and technical advances should help toward this evolution (189, (191) (192) (193) .
Because the PATH Statement focused on prediction in randomized trials, we did not explore the use of observational data-and when they may be sufficiently debiased for reliable identification of HTE (10, 194, 195) . In addition, there is an evolving set of tools for data-driven approaches to predicting patient benefit, including machine-learning techniques (28, 196, 197) . The PATH Statement should thus be understood as a formative first step (along a much longer path) toward the goal of personalized predictions of treatment benefit using the best available evidence. 
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